Ticker Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.

Aditya Birla Money Limited

Aditya Birla Money Limited

Morepen Laboratories Ltd

Symbol : MOREPENLAB | BSE Code : 500288 | Sector : PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

37.810.61 (1.64%)
02-Apr-2026 | 12:00
Loading

Market Cap (₹ Cr.)

2,038.39
Today’s High / Low
38.27
35.17
52 Week High / Low
70.50
33.05
37.980.77 (2.07%)
02-Apr-2026 | 12:00
Loading

Market Cap (₹ Cr.)

2,038.94
Today’s High / Low
38.26
35.18
52 Week High / Low
70.40
33.44
37.810.61 (1.64%)
02-Apr-2026 | 12:00

Turnover (₹ Cr.)

82,717,186,200.00
Today’s High / Low
51,993
50,172.00
37.810.61 (1.64%)
02-Apr-2026 | 12:00

Turnover (₹ Cr.)

0.00
Today’s High / Low
0
0.00
OVERVIEW
  • Open
  • 35.85
  • Prev. Close
  • 37.20
  • High
  • 38.27
  • Low
  • 35.17
  • Market Cap (₹ Cr.)
  • 2,038.39
  • 52 Week High
  • 70.50
  • 52 Week Low
  • 33.05
  • Traded Volume (Lacs)
  • 3,831,585
  • Traded Value (Cr)
  • Dividend Yield
  • 0.54
  • Face Value
  • 2.00
  • EPS
  • 1.04
  • P/E
  • 35.78
  • Beta (1 year)
  • 1.02
OVERVIEW
  • Open
  • 36.25
  • Prev. Close
  • 37.21
  • High
  • 38.26
  • Low
  • 35.18
  • Market Cap (₹ Cr.)
  • 2,038.94
  • 52 Week High
  • 70.40
  • 52 Week Low
  • 33.44
  • Traded Volume (Lacs)
  • 350,544
  • Traded Value (Cr)
  • Dividend Yield
  • 0.54
  • Face Value
  • 2.00
  • EPS
  • 1.04
  • P/E
  • 35.78
  • Beta (1 year)
OVERVIEW
  • Open
  • 50,760.00
  • Prev. Close
  • 51,784.60
  • High
  • 51,993
  • Low
  • 50,172.00
  • Strike Price
  • 0.00
  • Open Interest(Nos.)
  • 2,484,930.00
  • OI Change %
  • 3.84
  • Volume(Lacs)
  • 3.84
  • Lot Size
  • 30.00
  • Average Price
  • 50,944.43
  • OI Difference
  • 91,800.00
  • Previous OI
  • 2,393,130.00
OVERVIEW
  • Open
  • 0.00
  • Prev. Close
  • 1,940.00
  • High
  • 0
  • Low
  • 0.00
  • Strike Price
  • 24,950.00
  • Open Interest(Nos.)
  • 2,860.00
  • OI Change %
  • 0.00
  • Volume(Lacs)
  • 0.00
  • Lot Size
  • 65.00
  • Average Price
  • 0.00
  • OI Difference
  • 0.00
  • Previous OI
  • 2,860.00
LAST 5 DAYS

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY 20.81%

  • 02/04/2026 BSE
    0.77(2.07)
    Close Price: ₹ 37.98
    Volume: 350,544.00

    02-Apr-2026
  • 02/04/2026 BSE
    3.41(10.09)
    Close Price: ₹ 37.21
    Volume: 383,084.00

    01-Apr-2026
  • 02/04/2026 BSE
    -2.33(-6.45)
    Close Price: ₹ 33.80
    Volume: 279,370.00

    30-Mar-2026
  • 02/04/2026 BSE
    -0.84(-2.27)
    Close Price: ₹ 36.13
    Volume: 456,711.00

    27-Mar-2026
  • 02/04/2026 BSE
    0.42(1.15)
    Close Price: ₹ 36.97
    Volume: 195,360.00

    25-Mar-2026

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY 20.81%

  • Stock Absolute
  • 0.65
  • -10.72
  • -24.62
  • 41.64
  • 9.12
  • Returns
  • 1W
  • 1M
  • 1Y
  • 3Y
  • 5Y
  • Sensex Absolute
  • -2.84
  • -8.85
  • -3.80
  • 23.73
  • 46.18
NEWS

Morepen Lab secures multi-year order of Rs 825 cr under CDMO segment

23-Feb-2026

No Data Available

Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore (USD 91 million) from a leading global pharma major.

Supplies under the mandate are expected to commence within the next 4–5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.

23
Feb

Morepen Lab secures multi-year order of Rs 825 cr under CDMO segment



23
Feb

Morepen Laboratories Ltd leads gainers in 'A' group



23
Feb

Morepen Labs surges after bagging Rs 825 crore CDMO contract from global pharma firm



FINANCIAL DATA

In Cr.

Mar 2025Mar 2024Mar 2023
SOURCES OF FUNDS :   
Share Capital 109.58102.23102.23
Reserves Total 1,071.92786.80677.89
Equity Share Warrants0.000.000.00
Equity Application Money0.000.000.00
Read More
Mar 2025Mar 2024Mar 2023
INCOME :   
Sales Turnover 1,554.541,537.591,338.88
Excise Duty0.000.000.00
Net Sales1,554.541,537.591,338.88
Other Income 15.7212.575.76
Read More
ParticularsDec 2025Sep 2025Jun 2025
Gross Sales 457.57369.53391.28
Excise Duty 000
Net Sales 457.57369.53391.28
Other Operating Income 000
Other Income  3.935.754.09
Read More
Category No. Of Shares Percentage (%)
Total Foreign 53770297 9.81
Total Institutions 6866287 1.25
Total Govt Holding 60000 0.01
Total Non Promoter Corporate Holding 10071341 1.84
Total Promoters 195371588 35.66
Total Public & others 281,814,186.00 51.43
Total 100.00 100.00
Read More
CORPORATE ACTIONS
Record Date Ex-Bonus Date Ratio
nodata
No Data Available!!!
Read More
Read More
Record Date Split Date Face Value Before Face Value After
22-11-2000 07-11-2000 10 2
22-11-2000 06-11-2000 10 2
Read More
ANNOUNCEMENT DATE EX DIVIDEND DATE DIVIDEND (%) DIVIDEND TYPE
12-05-2025 29-08-2025 10 Final
Read More
PREMIUM (₹) RATIO RECORD DATE EX RIGHTS DATE
20 0:0 08-12-1995 13-11-1995
Read More
FROM DATE EX TO DATE AGENDA
10-02-2026 NA Morepen Laboratories Ltdhas in...
14-11-2025 NA Morepen Laboratories Ltdhas in...
06-09-2025 NA AGM 06/09/2025 The notice o...
30-08-2025 NA Intimation For Fixation Of Rec...
29-08-2025 NA 10% Final Dividend
COMPANY INFO

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.

The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.

Morepen Laboratories Limited was established in 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride.

During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial productio

Read More
Get Free Demat Account
Captcha Image